Francois A. Lemonnier

Francois A. Lemonnier

Auto-generated profile, based on publicly available information

Francois A. Lemonnier

Unite "Immunite Cellulaire Antivirale", Institut Pasteur, Paris, France.

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 1999 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
FTFlorence Tilloy
Florence Tilloy
ETEmmanuel Treiner
Emmanuel Treiner
SPSe-Ho Park
Se-Ho Park
CGCorinne Garcia
Corinne Garcia
FLFrançois Lemonnier
François Lemonnier
OLOlivier Lantz
Olivier Lantz
We describe here a new subset of T cells, found in humans, mice, and cattle. These cells bear a canonical T cell receptor (TCR) α chain containing hAV7S2 and AJ33 in humans and the homologous AV19-AJ33 in mice and cattle with a CDR3 of constant length. These T cells are CD4−CD8− double-negative (DN) T cells in the three species and also CD8αα in humans. In humans, their frequency was ∼1/10 in DN, 1/50 in CD8α+, and 1/6,000 in CD4+ lymphocytes, and they display an activated/memory phenotype (CD45RAloCD45RO+). They preferentially use hBV2S1 and hBV13 segments and have an oligoclonal Vβ repertoire suggesting peripheral expansions. These cells were present in major histocompatibility complex (MHC) class II– and transporter associated with antigen processing (TAP)-deficient humans and mice and also in classical MHC class I– and CD1-deficient mice but were absent from β2-microglobulin–deficient mice, indicating their probable selection by a nonclassical MHC class Ib molecule distinct from CD1. The conservation between mammalian species, the abundance, and the unique selection pattern suggest an important role for cells using this novel canonical TCR α chain.

15 February 2004 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
FAFabrice André
Fabrice André
NCNathalie Chaput
Nathalie Chaput
NSNöel E. C. Schartz
Nöel E. C. Schartz
CFCaroline Flament
Caroline Flament
NANathalie Aubert
Nathalie Aubert
LZLaurence Zitvogel
Laurence Zitvogel
Current immunization protocols in cancer patients involve CTL-defined tumor peptides. Mature dendritic cells (DC) are the most potent APCs for the priming of naive CD8+ T cells, eventually leading to tumor eradication. Because DC can secrete MHC class I-bearing exosomes, we addressed whether exosomes pulsed with synthetic peptides could subserve the DC function consisting in MHC class I-restricted, peptide-specific CTL priming in vitro and in vivo. The priming of CTL restricted by HLA-A2 molecules and specific for melanoma peptides was performed: 1) using in vitro stimulations of total blood lymphocytes with autologous DC pulsed with GMP-manufactured autologous exosomes in a series of normal volunteers; 2) in HLA-A2 transgenic mice (HHD2) using exosomes harboring functional HLA-A2/Mart1 peptide complexes. In this study, we show that: 1) DC release abundant MHC class I/peptide complexes transferred within exosomes to other naive DC for efficient CD8+ T cell priming in vitro; 2) exosomes require nature’s adjuvants (mature DC) to efficiently promote the differentiation of melanoma-specific effector T lymphocytes producing IFN-γ (Tc1) effector lymphocytes in HLA-A2 transgenic mice (HHD2). These data imply that exosomes might be a transfer mechanism of functional MHC class I/peptide complexes to DC for efficient CTL activation in vivo.

16 June 1997 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SPSteve Pascolo
Steve Pascolo
NBNathalie Bervas
Nathalie Bervas
JUJan M. Ure
Jan M. Ure
ASAustin G. Smith
Austin G. Smith
FLFrançois A. Lemonnier
François A. Lemonnier
BPBéatrice Pérarnau
Béatrice Pérarnau
Three different HLA-A2.1 monochains were engineered in which either the human or mouse β2-microglobulin (β2m) is covalently linked to the NH2 terminus of the heavy chain by a 15– amino acid long peptide: HHH, entirely human, HHD, with the mouse H-2Db α3, transmembrane, and cytoplasmic domains, and MHD, homologous to HHD but linked to the mouse β2mb. The cell surface expression and immunological capacities of the three monochains were compared with transfected cells, and the selected HHD construct was introduced by transgenesis in H-2Db−/− β2m−/− double knockout mice. Expression of this monochain restores a sizable peripheral CD8+ T cell repertoire essentially educated on the transgenic human molecule. Consequently, infected HHD, H-2Db−/− β2m−/− mice generate only HLA-A2.1–restricted CD8+ CTL responses against influenza A and vaccinia viruses. Interestingly, the CTL response to influenza A virus is mostly, if not exclusively, directed to the 58-66 matrix peptide which is the HLA-A2.1–restricted immunodominant epitope in humans. Such mice might constitute a versatile animal model for the study of HLA-A2.1–restricted CTL responses of vaccine interest.

15 February 2004 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NCNathalie Chaput
Nathalie Chaput
NSNöel E. C. Schartz
Nöel E. C. Schartz
FAFabrice André
Fabrice André
JTJulien TaïeB
Julien TaïeB
SNSophie Novault
Sophie Novault
LZLaurence Zitvogel
Laurence Zitvogel
Ideal vaccines should be stable, safe, molecularly defined, and out-of-shelf reagents efficient at triggering effector and memory Ag-specific T cell-based immune responses. Dendritic cell-derived exosomes could be considered as novel peptide-based vaccines because exosomes harbor a discrete set of proteins, bear functional MHC class I and II molecules that can be loaded with synthetic peptides of choice, and are stable reagents that were safely used in pioneering phase I studies. However, we showed in part I that exosomes are efficient to promote primary MHC class I-restricted effector CD8+ T cell responses only when transferred onto mature DC in vivo. In this work, we bring evidence that among the clinically available reagents, Toll-like receptor 3 and 9 ligands are elective adjuvants capable of triggering efficient MHC-restricted CD8+ T cell responses when combined to exosomes. Exosome immunogenicity across species allowed to verify the efficacy of good manufactory procedures-manufactured human exosomes admixed with CpG oligonucleotides in prophylactic and therapeutic settings of melanoma in HLA-A2 transgenic mice. CpG adjuvants appear to be ideal adjuvants for exosome-based cancer vaccines.

4 April 2005 in Journal of Experimental Medicine
Verified
Journal Article
Open access
SJSofia Johansson
Sofia Johansson
MJMaria Johansson
Maria Johansson
EREleftheria Rosmaraki
Eleftheria Rosmaraki
GVGustaf Vahlne
Gustaf Vahlne
RMRamit Mehr
Ramit Mehr
PHPetter HögLund
Petter HögLund
The ability of murine NK cells to reject cells lacking self MHC class I expression results from an in vivo education process. To study the impact of individual MHC class I alleles on this process, we generated mice expressing single MHC class I alleles (Kb, Db, Dd, or Ld) or combinations of two or more alleles. All single MHC class I mice rejected MHC class I–deficient cells in an NK cell–dependent way. Expression of Kb or Dd conveyed strong rejection of MHC class I–deficient cells, whereas the expression of Db or Ld resulted in weaker responses. The educating impact of weak ligands (Db and Ld) was further attenuated by the introduction of additional MHC class I alleles, whereas strong ligands (Kb and Dd) maintained their educating impact under such conditions. An analysis of activating and inhibitory receptors in single MHC class I mice suggested that the educating impact of a given MHC class I molecule was controlled both by the number of NK cells affected and by the strength of each MHC class I–Ly49 receptor interaction, indicating that NK cell education may be regulated by a combination of qualitative and quantitative events.

30 September 2004 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
APAnthony Pajot
Anthony Pajot
MMMarie‐Louise Michel
Marie‐Louise Michel
NFNicolas Fazilleau
Nicolas Fazilleau
VPVéronique Pancré
Véronique Pancré
CAClaude Auriault
Claude Auriault
YLYu‐Chun Lone
Yu‐Chun Lone
HLA‐A2.1‐/HLA‐DR1‐transgenic H‐2 class I‐/class II‐knockout mice were created and their immunological potential evaluated in response to hepatitis B DNA vaccine. Every single immunized mouse developed hepatitis B virus‐specific antibodies, HLA‐DR1‐restricted helper, and HLA‐A2.1‐restricted cytolytic T cell responses directed at the same immunodominant epitopes as those identified in naturally infected or vaccinated humans. These mice were specifically protected against a hepatitis B‐recombinant vaccinia virus infection with a 10,000‐fold or more reduction of the virus load at day 4 post‐challenge. These mice represent a unique in vivo experimental model for human immune function studies without any interference with mouse MHC response which dwarfed the prediction of human responses. Furthermore, they enable the complete monitoring of immune adaptative responses for preclinical screening of candidate vaccines.